Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age, characterized by chronic anovulation, hyperandrogenism, and polycystic ovarian morphology. Letrozole, an aromatase inhibitor, has emerged as a first-line ovulation induction agent due to its superior ovulation and pregnancy rates compared to clomiphene citrate. Estradiol valerate, a synthetic estrogen, can be co-administered with letrozole to improve endometrial receptivity by enhancing endometrial thickness, vascularity, and pattern. This study aims to evaluate the effect of letrozole alone versus letrozole with estradiol valerate on endometrial development in these patients.
Women aged 20-35 years
Clinical diagnosis of PCOS (Rotterdam criteria)
Endocrine disorders other than PCOS
Endometrial pathology or uterine malformations
Allergy to letrozole or estradiol
Hormonal therapy within last 3 months
Parallel
Letrozole (Aromatase Inhibitors)
Drug30 participants with PCOs will receive tab letrozole 2.5mg 2 x OD for 5 days
Letrozole (Aromatase Inhibitors) + Estradiol valerate
Drug30 participants with PCOs will receive tab letrozole 2.5mg 2 x OD for 5 days plus tab Estradiol valerate 2mg OD for 12 days
Endometrial thickness (mm) on day of ovulation trigger
Endometrial thickness will be measured on Transvaginal ultrasound on 12th day in a 28 day menstrual cycle.
Pattern of endometrium (Trilaminar or Non-trilaminar) on the day of ovulation trigger
Endometrial pattern will be seen on Transvaginal ultrasound on 12th day in a 28 day menstrual cycle
Map coordinates are unavailable for these locations. Locations are shown below instead.
PakistanClick on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
